{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T13:55:12Z","timestamp":1794059712063,"version":"4.8.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R33CA302491"],"award-info":[{"award-number":["R33CA302491"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P50CA254838"],"award-info":[{"award-number":["P50CA254838"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Academy of Medicine Catalyst award, the Michelson Prize for Immunology, and the Geoffrey Beene Cancer Research Center of Memorial Sloan Kettering"},{"name":"Basic and Translational Immunology Postdoctoral Award granted by the Ludwig Center at Memorial Sloan Kettering"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat. Biomed. Eng"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Advances in generative protein design using artificial intelligence (AI) have enabled the rapid development of binders against heterogeneous targets, including tumour-associated antigens. Despite extensive biochemical characterization, these novel protein binders have had limited evaluation in candidate therapeutics, including chimaeric antigen receptor (CAR) T cells. Here we synthesize generative protein design workflows to screen 1,758 newly designed protein binders targeting BCMA, CD19 and CD22 for efficacy in scalable protein-binding, T-cell activation and in vivo killing assays. We characterize three main challenges that hinder the utility of de novo protein binders as CARs, including tonic signalling, occluded epitope engagement and off-target activity. We develop computational and experimental heuristics to overcome these limitations, including screens of sequence variants of individual parental structures, that retain on-target CAR activation while mitigating liabilities. Together, our framework accelerates the development of AI-designed proteins for future preclinical therapeutic screening, helping enable a new generation of cellular therapies.<\/jats:p>","DOI":"10.1038\/s41551-026-01790-9","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T09:02:40Z","timestamp":1788944560000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Sequence and structural determinants of efficacious de novo chimaeric antigen receptors"],"prefix":"10.1038","author":[{"given":"Arthur","family":"Chow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8630-3667","authenticated-orcid":false,"given":"Hoyin","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruofan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benan N.","family":"Nalbant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Vehab","family":"Dozic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6553-2483","authenticated-orcid":false,"given":"Laura C.","family":"Kida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3789-2906","authenticated-orcid":false,"given":"Zeyu","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph R.","family":"Palmeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4179-4807","authenticated-orcid":false,"given":"Caleb A.","family":"Lareau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"1790_CR1","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","volume":"614","author":"L Labanieh","year":"2023","unstructured":"Labanieh, L. & Mackall, C. L. CAR immune cells: design principles, resistance and the next generation. Nature 614, 635\u2013648 (2023).","journal-title":"Nature"},{"key":"1790_CR2","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","volume":"10","author":"I Zugasti","year":"2025","unstructured":"Zugasti, I. et al. CAR-T cell therapy for cancer: current challenges and future directions. Signal Transduct. Target. Ther. 10, 210 (2025).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1790_CR3","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41587-025-02555-6","volume":"43","author":"M Senior","year":"2025","unstructured":"Senior, M. Fresh from the biotech pipeline: FDA approvals settle in 2024, but what next? Nat. Biotechnol. 43, 159\u2013165 (2025).","journal-title":"Nat. Biotechnol."},{"key":"1790_CR4","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June, C. H., O\u2019Connor, R. S., Kawalekar, O. U., Ghassemi, S. & Milone, M. C. CAR T cell immunotherapy for human cancer. Science 359, 1361\u20131365 (2018).","journal-title":"Science"},{"key":"1790_CR5","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.jcyt.2024.02.024","volume":"26","author":"MA Nix","year":"2024","unstructured":"Nix, M. A. & Wiita, A. P. Alternative target recognition elements for chimeric antigen receptor (CAR) T cells: beyond standard antibody fragments. Cytotherapy 26, 729\u2013738 (2024).","journal-title":"Cytotherapy"},{"key":"1790_CR6","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.cell.2023.12.028","volume":"187","author":"T Kortemme","year":"2024","unstructured":"Kortemme, T. De novo protein design\u2014from new structures to programmable functions. Cell 187, 526\u2013544 (2024).","journal-title":"Cell"},{"key":"1790_CR7","doi-asserted-by":"crossref","unstructured":"Pacesa, M. et al. One-shot design of functional protein binders with BindCraft. Nature 646, 483\u2013492 (2025).","DOI":"10.1038\/s41586-025-09429-6"},{"key":"1790_CR8","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/s41586-023-06415-8","volume":"620","author":"JL Watson","year":"2023","unstructured":"Watson, J. L. et al. De novo design of protein structure and function with RFdiffusion. Nature 620, 1089\u20131100 (2023).","journal-title":"Nature"},{"key":"1790_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38328-5","volume":"14","author":"NR Bennett","year":"2023","unstructured":"Bennett, N. R. et al. Improving de novo protein binder design with deep learning. Nat. Commun. 14, 2625 (2023).","journal-title":"Nat. Commun."},{"key":"1790_CR10","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1126\/science.abn2100","volume":"377","author":"J Wang","year":"2022","unstructured":"Wang, J. et al. Scaffolding protein functional sites using deep learning. Science 377, 387\u2013394 (2022).","journal-title":"Science"},{"key":"1790_CR11","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/s41586-021-04184-w","volume":"600","author":"I Anishchenko","year":"2021","unstructured":"Anishchenko, I. et al. De novo protein design by deep network hallucination. Nature 600, 547\u2013552 (2021).","journal-title":"Nature"},{"key":"1790_CR12","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature11600","volume":"491","author":"N Koga","year":"2012","unstructured":"Koga, N. et al. Principles for designing ideal protein structures. Nature 491, 222\u2013227 (2012).","journal-title":"Nature"},{"key":"1790_CR13","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/s41586-022-04654-9","volume":"605","author":"L Cao","year":"2022","unstructured":"Cao, L. et al. Design of protein-binding proteins from the target structure alone. Nature 605, 551\u2013560 (2022).","journal-title":"Nature"},{"key":"1790_CR14","doi-asserted-by":"publisher","first-page":"4732","DOI":"10.1038\/s41467-023-40303-z","volume":"14","author":"T Sar\u00e9n","year":"2023","unstructured":"Sar\u00e9n, T. et al. Complementarity-determining region clustering may cause CAR-T cell dysfunction. Nat. Commun. 14, 4732 (2023).","journal-title":"Nat. Commun."},{"key":"1790_CR15","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/s41419-019-1711-1","volume":"10","author":"Z Zhang","year":"2019","unstructured":"Zhang, Z. et al. Modified CAR T cells targeting membrane-proximal epitope of mesothelin enhances the antitumor function against large solid tumor. Cell Death Dis. 10, 476 (2019).","journal-title":"Cell Death Dis."},{"key":"1790_CR16","doi-asserted-by":"publisher","unstructured":"Weinberg, Z. Y. et al. De novo-designed minibinders expand the synthetic biology sensing repertoire. eLife 13, RP96154 https:\/\/doi.org\/10.7554\/elife.96154.2 (2024).","DOI":"10.7554\/elife.96154.2"},{"key":"1790_CR17","doi-asserted-by":"publisher","unstructured":"Mergen, M. et al. Engineering de novo binder CAR-T cell therapies with generative AI. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2024.11.25.625151 (2024).","DOI":"10.1101\/2024.11.25.625151"},{"key":"1790_CR18","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1038\/s41551-024-01258-8","volume":"8","author":"Z Xia","year":"2024","unstructured":"Xia, Z. et al. Targeting overexpressed antigens in glioblastoma via CAR T cells with computationally designed high-affinity protein binders. Nat. Biomed. Eng. 8, 1634\u20131650 (2024).","journal-title":"Nat. Biomed. Eng."},{"key":"1790_CR19","doi-asserted-by":"publisher","first-page":"8736","DOI":"10.1038\/s41467-026-76760-5","volume":"17","author":"B Broske","year":"2026","unstructured":"Broske, B. et al. AI-enabled discovery and biochemical optimization of minibinders targeting cancer cell-surface proteins. Nat. Commun. 17, 8736 (2026).","journal-title":"Nat. Commun."},{"key":"1790_CR20","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","volume":"34","author":"N Shah","year":"2020","unstructured":"Shah, N., Chari, A., Scott, E., Mezzi, K. & Usmani, S. Z. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia 34, 985\u20131005 (2020).","journal-title":"Leukemia"},{"key":"1790_CR21","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1126\/science.add2187","volume":"378","author":"J Dauparas","year":"2022","unstructured":"Dauparas, J. et al. Robust deep learning-based protein sequence design using ProteinMPNN. Science 378, 49\u201356 (2022).","journal-title":"Science"},{"key":"1790_CR22","doi-asserted-by":"publisher","unstructured":"Evans, R. et al. Protein complex prediction with AlphaFold-Multimer. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2021.10.04.463034 (2022).","DOI":"10.1101\/2021.10.04.463034"},{"key":"1790_CR23","doi-asserted-by":"publisher","unstructured":"Cotet, T.-S. et al. Crowdsourced protein design: lessons from the Adaptyv EGFR binder competition. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2025.04.17.648362 (2025).","DOI":"10.1101\/2025.04.17.648362"},{"key":"1790_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37701-8","volume":"14","author":"LF Krapp","year":"2023","unstructured":"Krapp, L. F., Abriata, L. A., Cort\u00e9s Rodriguez, F. & Dal Peraro, M. PeSTo: parameter-free geometric deep learning for accurate prediction of protein binding interfaces. Nat. Commun. 14, 2175 (2023).","journal-title":"Nat. Commun."},{"key":"1790_CR25","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1002\/eji.201646837","volume":"47","author":"D Cibri\u00e1n","year":"2017","unstructured":"Cibri\u00e1n, D. & S\u00e1nchez-Madrid, F. CD69: from activation marker to metabolic gatekeeper. Eur. J. Immunol. 47, 946\u2013953 (2017).","journal-title":"Eur. J. Immunol."},{"key":"1790_CR26","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.omtm.2020.01.012","volume":"16","author":"D Bloemberg","year":"2020","unstructured":"Bloemberg, D. et al. A high-throughput method for characterizing novel chimeric antigen receptors in Jurkat cells. Mol. Ther. Methods Clin. Dev. 16, 238\u2013254 (2020).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"1790_CR27","doi-asserted-by":"publisher","first-page":"1512494","DOI":"10.3389\/fimmu.2025.1512494","volume":"16","author":"HR Alfar","year":"2025","unstructured":"Alfar, H. R., Chen, C., Lachacz, E., Tang, W. & Zhang, Y. Clinical evidence of immunogenicity of CAR-T cell therapies and its implication in the clinical development of CAR-T drug products. Front. Immunol. 16, 1512494 (2025).","journal-title":"Front. Immunol."},{"key":"1790_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-57192-z","volume":"16","author":"W Yang","year":"2025","unstructured":"Yang, W. et al. Design of high-affinity binders to immune modulating receptors for cancer immunotherapy. Nat. Commun. 16, 2001 (2025).","journal-title":"Nat. Commun."},{"key":"1790_CR29","doi-asserted-by":"publisher","first-page":"4305","DOI":"10.1016\/j.cell.2024.05.052","volume":"187","author":"S Berger","year":"2024","unstructured":"Berger, S. et al. Preclinical proof of principle for orally delivered Th17 antagonist miniproteins. Cell 187, 4305\u20134317.e18 (2024).","journal-title":"Cell"},{"key":"1790_CR30","doi-asserted-by":"publisher","unstructured":"Wohlwend, J. et al. BOLTZ-1 democratizing biomolecular interaction modeling. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2024.11.19.624167 (2025).","DOI":"10.1101\/2024.11.19.624167"},{"key":"1790_CR31","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/s41586-024-07601-y","volume":"631","author":"CA Goverde","year":"2024","unstructured":"Goverde, C. A. et al. Computational design of soluble and functional membrane protein analogues. Nature 631, 449\u2013458 (2024).","journal-title":"Nature"},{"key":"1790_CR32","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41422-023-00789-0","volume":"33","author":"J Chen","year":"2023","unstructured":"Chen, J. et al. Tuning charge density of chimeric antigen receptor optimizes tonic signaling and CAR-T cell fitness. Cell Res. 33, 341\u2013354 (2023).","journal-title":"Cell Res."},{"key":"1790_CR33","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41422-024-00936-1","volume":"34","author":"S Qiu","year":"2024","unstructured":"Qiu, S. et al. CAR-Toner: an AI-driven approach for CAR tonic signaling prediction and optimization. Cell Res. 34, 386\u2013388 (2024).","journal-title":"Cell Res."},{"key":"1790_CR34","doi-asserted-by":"publisher","first-page":"9543","DOI":"10.1073\/pnas.1819745116","volume":"116","author":"J Xu","year":"2019","unstructured":"Xu, J. et al. Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed\/refractory multiple myeloma. Proc. Natl Acad. Sci. USA 116, 9543\u20139551 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1790_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01886-9","volume":"22","author":"Y Zhang","year":"2023","unstructured":"Zhang, Y. et al. Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study. Mol. Cancer 22, 200 (2023).","journal-title":"Mol. Cancer"},{"key":"1790_CR36","doi-asserted-by":"crossref","unstructured":"Sappington, I. et al. Improved protein binder design using beta-pairing targeted RFdiffusion. Nat. Commun. 17, 1101 (2026).","DOI":"10.1038\/s41467-025-67866-3"},{"key":"1790_CR37","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/s41586-025-09248-9","volume":"644","author":"C Liu","year":"2025","unstructured":"Liu, C. et al. Diffusing protein binders to intrinsically disordered proteins. Nature 644, 809\u2013817 (2025).","journal-title":"Nature"},{"key":"1790_CR38","doi-asserted-by":"publisher","DOI":"10.1126\/science.adr8063","volume":"389","author":"K Wu","year":"2025","unstructured":"Wu, K. et al. Design of intrinsically disordered region binding proteins. Science 389, eadr8063 (2025).","journal-title":"Science"},{"key":"1790_CR39","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/S0140-6736(24)00746-3","volume":"404","author":"MJ Frank","year":"2024","unstructured":"Frank, M. J. et al. CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study. Lancet 404, 353\u2013363 (2024).","journal-title":"Lancet"},{"key":"1790_CR40","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1038\/s41375-024-02220-y","volume":"38","author":"LM Schultz","year":"2024","unstructured":"Schultz, L. M. et al. CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: phase 1b results. Leukemia 38, 963\u2013968 (2024).","journal-title":"Leukemia"},{"key":"1790_CR41","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.str.2026.02.012","volume":"34","author":"Y Dai","year":"2026","unstructured":"Dai, Y. et al. Off-target reactivity in clinical monoclonal antibodies. Structure 34, 747\u2013757.e5 (2026).","journal-title":"Structure"},{"key":"1790_CR42","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/s41587-023-01763-2","volume":"42","author":"BL Hie","year":"2023","unstructured":"Hie, B. L. et al. Efficient evolution of human antibodies from general protein language models. Nat. Biotechnol. 42, 275\u2013283 (2023).","journal-title":"Nat. Biotechnol."},{"key":"1790_CR43","doi-asserted-by":"publisher","unstructured":"Dunbrack, R. R\u0113s ipSAE loquunt: What\u2032s wrong with AlphaFold\u2019s ipTM score and how to fix it. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2025.02.10.637595 (2025).","DOI":"10.1101\/2025.02.10.637595"},{"key":"1790_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-48528-0","volume":"13","author":"J Seigner","year":"2023","unstructured":"Seigner, J. et al. Solving the mystery of the FMC63-CD19 affinity. Sci. Rep. 13, 23024 (2023).","journal-title":"Sci. Rep."},{"key":"1790_CR45","doi-asserted-by":"publisher","first-page":"100966","DOI":"10.1016\/j.jbc.2021.100966","volume":"297","author":"J Ere\u00f1o-Orbea","year":"2021","unstructured":"Ere\u00f1o-Orbea, J. et al. Structural details of monoclonal antibody m971 recognition of the membrane-proximal domain of CD22. J. Biol. Chem. 297, 100966 (2021).","journal-title":"J. Biol. Chem."},{"key":"1790_CR46","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1182\/blood.2021010833","volume":"137","author":"LSH Lee","year":"2021","unstructured":"Lee, L. S. H. & Yong, K. L. BCMA CARs in multiple myeloma: room for more? Blood 137, 2859\u20132860 (2021).","journal-title":"Blood"},{"key":"1790_CR47","doi-asserted-by":"publisher","first-page":"886546","DOI":"10.3389\/fimmu.2022.886546","volume":"13","author":"AN Khan","year":"2022","unstructured":"Khan, A. N. et al. Immunogenicity of CAR-T cell therapeutics: evidence, mechanism and mitigation. Front. Immunol. 13, 886546 (2022).","journal-title":"Front. Immunol."},{"key":"1790_CR48","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.4049\/jimmunol.1700893","volume":"199","author":"V Jurtz","year":"2017","unstructured":"Jurtz, V. et al. NetMHCpan-4.0: improved peptide-MHC class I interaction predictions integrating eluted ligand and peptide binding affinity data. J. Immunol. 199, 3360\u20133368 (2017).","journal-title":"J. Immunol."},{"key":"1790_CR49","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/s41591-019-0549-5","volume":"25","author":"S Ghorashian","year":"2019","unstructured":"Ghorashian, S. et al. Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. Nat. Med. 25, 1408\u20131414 (2019).","journal-title":"Nat. Med."},{"key":"1790_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38039-x","volume":"14","author":"SB Ebrahimi","year":"2023","unstructured":"Ebrahimi, S. B. & Samanta, D. Engineering protein-based therapeutics through structural and chemical design. Nat. Commun. 14, 2411 (2023).","journal-title":"Nat. Commun."},{"key":"1790_CR51","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1126\/science.adv3813","volume":"389","author":"KD Householder","year":"2025","unstructured":"Householder, K. D. et al. De novo design and structure of a peptide-centric TCR mimic binding module. Science 389, 375\u2013379 (2025).","journal-title":"Science"},{"key":"1790_CR52","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1126\/science.adv0422","volume":"389","author":"KH Johansen","year":"2025","unstructured":"Johansen, K. H. et al. De novo-designed pMHC binders facilitate T cell-mediated cytotoxicity toward cancer cells. Science 389, 380\u2013385 (2025).","journal-title":"Science"},{"key":"1790_CR53","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1126\/science.adv0185","volume":"389","author":"B Liu","year":"2025","unstructured":"Liu, B. et al. Design of high-specificity binders for peptide-MHC-I complexes. Science 389, 386\u2013391 (2025).","journal-title":"Science"},{"key":"1790_CR54","doi-asserted-by":"publisher","unstructured":"Muratspahi\u0107, E. et al. De novo design of miniproteins targeting GPCRs. Nature https:\/\/doi.org\/10.1038\/s41586-026-10656-8 (2026).","DOI":"10.1038\/s41586-026-10656-8"},{"key":"1790_CR55","doi-asserted-by":"publisher","unstructured":"Overath, M. D. et al. Predicting experimental success in DE Novo binder design: a meta-analysis of 3,766 experimentally characterised binders. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2025.08.14.670059 (2025).","DOI":"10.1101\/2025.08.14.670059"},{"key":"1790_CR56","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41586-023-05778-2","volume":"615","author":"AM Tousley","year":"2023","unstructured":"Tousley, A. M. et al. Co-opting signalling molecules enables logic-gated control of CAR T cells. Nature 615, 507\u2013516 (2023).","journal-title":"Nature"},{"key":"1790_CR57","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1038\/s41586-024-08366-0","volume":"638","author":"DI Piraner","year":"2025","unstructured":"Piraner, D. I. et al. Engineered receptors for soluble cellular communication and disease sensing. Nature 638, 805\u2013813 (2025).","journal-title":"Nature"},{"key":"1790_CR58","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1158\/2643-3230.BCD-20-0208","volume":"2","author":"RM Richards","year":"2021","unstructured":"Richards, R. M. et al. NOT-gated CD93 CAR T cells effectively target AML with minimized endothelial cross-reactivity. Blood Cancer Discov. 2, 648\u2013665 (2021).","journal-title":"Blood Cancer Discov."},{"key":"1790_CR59","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1016\/j.ccell.2021.11.005","volume":"39","author":"CA Lareau","year":"2021","unstructured":"Lareau, C. A., Parker, K. R. & Satpathy, A. T. Charting the tumor antigen maps drawn by single-cell genomics. Cancer Cell 39, 1553\u20131557 (2021).","journal-title":"Cancer Cell"},{"key":"1790_CR60","unstructured":"Chow, A., Chu, H. & Lareau, C. A. De novo CAR T reproducibility. GitHub https:\/\/github.com\/clareaulab\/denovo-cart-reproducibility (2026)."},{"key":"1790_CR61","unstructured":"Chu, H. CARPNN. GitHub https:\/\/github.com\/clareaulab\/CARPNN (2026)."}],"container-title":["Nature Biomedical Engineering"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41551-026-01790-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-026-01790-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-026-01790-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T09:02:45Z","timestamp":1788944565000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41551-026-01790-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":61,"alternative-id":["1790"],"URL":"https:\/\/doi.org\/10.1038\/s41551-026-01790-9","relation":{},"ISSN":["2157-846X"],"issn-type":[{"value":"2157-846X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"assertion":[{"value":"9 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Memorial Sloan Kettering has filed an international provisional patent (US2025 PPA63\/910,627) on the results described in this paper with A.C., H.C., R.L., B.N.N. and C.A.L. named as inventors. C.A.L. is a consultant to Cartography Biosciences. All other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}